5 news items
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
ATXI
FBIO
16 May 24
thank the trial investigators, the patients, our partner AnnJi Pharmaceutical Co. Ltd., and our internal team for their dedication to completing
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
ATXI
FBIO
15 May 24
Christopher Grunseich, M.D., Lasker Clinical Research Scholar and Investigator and Head of the Inherited Neuromuscular Diseases Unit at the National
Crude Oil Moves Lower; B. Riley Financial Shares Jump
AMST
ATXI
BOF
24 Apr 24
. (NASDAQ:RILY) shares were also up, gaining 44% to $31.25 after the company announced the results of an independent investigation showed
Why Teledyne Technologies Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
AMST
APDN
ATXI
24 Apr 24
. (NASDAQ:RILY) shares surged 29.9% to $28.20 after the company announced the results of an independent investigation showed the company and its
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
ATXI
FBIO
25 Mar 24
and Investigator and Head of the Inherited Neuromuscular Diseases Unit at the National Institute of Neurological Disorders and Stroke
- Prev
- 1
- Next